[1]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122-124+131.[doi:10.3969/j.issn.1671-7414.2018.06.032]
　ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):122-124+131.[doi:10.3969/j.issn.1671-7414.2018.06.032]
点击复制

血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年06期
页码:
122-124+131
栏目:
论著
出版日期:
2018-12-24

文章信息/Info

Title:
Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer
文章编号:
1671-7414(2018)06-122-04
作者:
张善弟1; 荆成宝2; 禹 梅2
1.安康市汉滨区第二医院,陕西安康 725021; 2.安康市中心医院,陕西安康 725000
Author(s):
ZHANG Shan-di1; JING Cheng-bao2; YU Mei2
1.the Second Hospital of Hanbin District in Ankang,Shaanxi Ankang 725021,China; 2.Ankang Central Hospital,Shaanxi Ankang 72500,China
关键词:
卵巢癌;  癌胚抗原(CEA);  糖类抗原(CA125);  人类附睾蛋白4(HE4)
分类号:
R737.31; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.06.032
文献标志码:
A
摘要:
目的 探讨血清中癌胚抗原(carcinogenic antigen,CEA)、糖链抗原125(CA125)和人附睾蛋白4(human epididymis secretary protein 4,HE4)联合检测在卵巢癌诊断中的临床价值。方法 采用西门子CentaurXP全自动化学发光免疫分析仪检测37例卵巢癌患者(卵巢癌组),42例卵巢良性病变患者(良性病变组)及40例健康者(对照组)血清CEA,CA125和HE4水平,分析比较各组间三项指标水平的差异,三组三项指标单项及联合检测阳性率的比较; 通过敏感度、特异度、阳性预测值评价血清CEA,CA125,HE4联合检测对卵巢癌的临床诊断价值。结果 卵巢癌组与良性卵巢病变组血清CEA,CA125,HE4水平比较差异均有统计学意义(t=6.1,6.0,4.8,均P<0.05); 良性病变组CA125水平与对照组比较差异有统计学意义(t=4.7,P<0.05); CEA和HE4良性病变组与对照组比较差异无统计学意义(t=1.8,0.3,均P>0.05); 卵巢癌组血清CEA,CA125和HE4单项、两两联合和三项联合检测阳性率分别是:32.4%,70.3%,78.4%,75.7%,81.8%83.8%和89.2%。卵巢癌组与良性病变组CEA,CA125,HE4单项,两两联合和三项联合检测比较差异有统计学意义(χ2=13.4～49.4,均P<0.05),卵巢癌组与正常对照组CEA,CA125,HE4单项,两两联合和三项联合检测比较差异有统计学意义(χ2=20.0～49.5,均P<0.05); 三项联合检测敏感度为89.2%,高于各单项和两两联合检测的敏感度。结论 CEA,CA125和HE4三项联合检测敏感度高于各单项及两两联合检测的敏感度,三项联合检测能够提高卵巢癌的诊断水平。
Abstract:
Objective To investigate the clinical value ofserum carcinogenic antigen(CEA),glycochain antigen 125(CA125)and human epididymis secretein 4(HE4)in the diagnosis of ovarian cancer.Methods The serum CEA,CA125 and HE4 level of 37 patients with ovarian cancer(ovarian cancer group),42 patients with benign ovarian lesions(benign lesions group)and 40 healthy patients(control group)were tested with the fully automatic chemiluminescent immunoassay of Siemens Centaur XP.and the differences of three index levels among the three groups were analyzed,and the positive rates were compared among three groups of three indicators.Evaluated of the clinical diagnostic value of serum CEA,CA125 and HE4 for ovarian cancer by sensitivity,specificity and positive prediction.Results The serum levels of ovarian carcinoma group and benign ovarian lesions group were statistically significant(t=4.8～6.1,all P<0.05).The concentration of CA125 inbenign lesion group was statistically significant(t=4.7,P<0.05).Therewas no statistically significant comparison between the CEA and HE4 benign control groups and the health group(χ2=1.8,0.3,all P>0.05).The positive rates of serum CEA,CA125 and HE4,combined and combined were 32.4%,70.3%,78.4%,75.7%,81.8%,83.8% and 89.2% respectively in ovarian carcinoma group.The ovarian cancer group was statistically significant compared with the benign lesion group(χ2=13.4～49.4,P<0.05).The ovarian cancer group was statistically significant compared with the normal control group(χ2=20.0～49.5,P<0.05).The sensitivity of ovarian cancer detection,89.2% of the sensitivity of the three joint tests,was higher than the sensitivityof each individual and two joint tests.Conclusion Thesensitivity of CEA,CA125,and HE4 was higher than that of individual two combined tests.

参考文献/References:

[1] De Angelis R,Sant M.Coleman MP,et al.Cancer survival in Europe 1997～2007 by country and age:results of EUROCARE-5-a population-based studly[J].Lancet Oncology,2014.15(1):23-34.
[2] 陈 辰,戴 楠,高玲娟,等.3种血清指标联合检测对卵巢癌早期诊断的价值[J].国际检验医学杂志,2017,38(1):68-70.
Chen C,Dai N,Gao LJ,et al.Clinical significance of the combineddetection of 3 serum markers in early diagnosis of ovarian cancer[J].International Journal of Laboratory Medicine,2017,38(1):68-70.
[3] 侯娟娟,虎淑妍,刘婷婷,等.血清肿瘤标准物在卵巢癌早期诊断中的临床价值[J].中国免疫学杂志,2014,16(8):1101-1104,1107.
Hou JJ,Hu SY,Liu TT,et al.Clinical value of serum tumor markey in early diagnosis of ovarian cancer[J].Chinese Journal of Immunology,2014,16(8):1101-1104,1107.
[4] 罗贤波.CA125,CA19-9,CEA联合检测在卵巢癌诊断中的价值[J].中国医疗前沿,2009,4(6):77-78.
Luo XB.Value of combined detection of CA125,C A19-9 and CEA for diagnosis of ovarian carcinoma[J].China Healthcare Frontier,2009,4(6):77-78.
[5] 宋晓翠,张文珺,腾洪涛,等.血清HE4,CA125联合检测在卵巢癌术后复发诊断中的应用[J].山西医药,2012,52(14):75-76.
Song XC,Zhang WJ,Teng HT,et al.The application of serum HE4 andCA125 in the diagnosis of postoperative recurrence of ovarian cancer[J].Shandong Medicine Journal,2012,52(14):75-76.
[6] 洪 波.血清CA125,AFP,CEA联合检测在卵巢癌中的运用[J].江西医学院学报,2006,45(5):80-84.
Hong B.Serum CA125,AFP and CEA in the application of ovarian cancer[J].Journal of Jiangxi Medical College,2006,45(5):80-84.
[7] 沈泽忠,甘洁琼.TSGF,CA125及CEA联合检测在卵巢癌早期诊断中的应用[J].国际医药卫生导报,2018,14(1):79-81.
Shen ZZ,Gan JQ.TSGF,CA125 and CEA in the early diagnosis of ovarian cancer[J].International Medical and Health Herald,2018,14(1):79-81.
[8] 王兰兰,许化溪.临床免疫学检验[M].5版.北京:人民卫生出版社,2014:333-334.
Wang LL,Xu HX.Clinical Immunology test[M].5th Edition.Beijing:People's Health Publishing House,2014:333-334.
[9] 杨洪鹏,王枭旻,王 雪.人附睾蛋白4,AFP对卵巢癌诊断价值分析[J].实用癌症杂志,2015,30(9):1287-1289.
Yang HP,Wang XM,Wang X.Value of human epididymal protein4 and alpha-fetoprotein in the diagnosis of ovarian cancer[J].Practical Journal Cancer,2015,30(9):1287-1289.
[10] 董 丽,昌晓红,叶 雪,等.血清人附睾分泌蛋白4和CA125水平检测在卵巢恶性肿瘤中的诊断价值[J].中华妇产科杂志,2008,43(12):931-936.
Dong L,Chang XH,Ye X,et al.The value of serum human epididymis secretion protein 4 and CA125 assay in the diagnosis of ovarian malgnancy[J].ChineseJournal of Obstet Gynaecology,2008,43(12):931-936.
[11] 潘秀芳,郑志昂,麦 燕.血清附睾蛋白4,糖类抗原125及19-9水平在老年卵巢癌诊断及病理类型鉴别中的临床价值[J].中国老年学杂志,2015,35(12):3343-3344.
Pan XF,Zheng ZA,Mai Y.Serum epididymis protein 4,carbohydrate angen 125 and 19-9 levels in the diagnosis and pathological type differentiation of senile ovarian ca ncer[J].Chinese Journal of Gerontology,2015,35(12):3343-3344.
[12] 闫先侠,孙 晓,张 华,等.血清人附睾蛋白4联合检测在卵巢癌诊断中的应用[J].现代检验医学杂志,2015,30(1):134-136.
Yan XX,Sun X,Zhang H,et al.Application of serum human epididymal protein 4 in the diagnosis of ovarian cancer[J].Journal of Modern Laboratory Medicine,2015,30(1):134-136.
[13] 朱自力,戴伟萍,肖春红,等.血清HE4,CA125联合ROMA指数在卵巢癌预测和诊断中的应用[J].现代检验医学杂志,2014,29(2):76-77,80.
Zhu ZL,Dai WP,Xiao CH,et al.Value of combined assays of human epididymis protein 4,CA125 and ROMA index in patients with ovarian cancer[J]Journal of Modern Laboratory Medicine,2014,9(2):76-77,80.
[14] 张保平,刘 珊,董 莉,等.血清HE4和CA125检测及ROMA模型在恶性卵巢癌诊断中的应用[J].现代检验医学杂志,2014,29(1):76-78,82.
Zhang BP,Liu S,Dong L,et al.Application of detecting serum HE4 and CA125 and ROMA model in malignant ovarian cancer diagnosis[J].Journal of ModernLaboratory Medicine,2014,29(1):76-78,82.

相似文献/References:

[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
　GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(06):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
[2]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
　ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6 in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(06):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
[3]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
　ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(06):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[4]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
　XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[5]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
　ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(06):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[6]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR, RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(06):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
　MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[8]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
　LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]侯 娟,蒋树立,滕长财.基于TCGA 数据库卵巢癌患者的miR-301b 表达量与生存状况生物信息学分析[J].现代检验医学杂志,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
　HOU Juan,JIANG Shu-li,TENG Chang-cai.Bioinformatics Analysis of Mir-301b Expression and Survival Status of Patients with Ovarian Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(06):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]

备注/Memo

备注/Memo:
作者简介:张善弟(1964-),男,本科,副主任技师,专业:临床检验,E-mail:2407259241@qq.com。
通讯作者:禹 梅,Tel:13992518339,E-mail:812486136@qq.com。
更新日期/Last Update: 2018-11-30